A phase 1b/II study of cancer stemness inhibitor napabucasin in combination with gemcitabine (gem) & nab-paclitaxel (nabptx) in metastatic pancreatic adenocarcinoma (mpdac) patients (pts)

T. Bekaii-Saab, A. Starodub, B. El-Rayes, B. O'Neil, S. Shahda, K. Ciombor, A. Noonan, W. Hanna, A. Sehdev, W. Shaib, S. Mikhail, A. Neki, C. Oh, Y. Z. Li, W. Li, L. Borodyansky, C. J. Li

Research output: Contribution to journalArticle

7 Scopus citations
Original languageEnglish (US)
Pages (from-to)iii150
JournalAnnals of oncology : official journal of the European Society for Medical Oncology
Volume28
DOIs
StatePublished - Jun 1 2017

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Bekaii-Saab, T., Starodub, A., El-Rayes, B., O'Neil, B., Shahda, S., Ciombor, K., Noonan, A., Hanna, W., Sehdev, A., Shaib, W., Mikhail, S., Neki, A., Oh, C., Li, Y. Z., Li, W., Borodyansky, L., & Li, C. J. (2017). A phase 1b/II study of cancer stemness inhibitor napabucasin in combination with gemcitabine (gem) & nab-paclitaxel (nabptx) in metastatic pancreatic adenocarcinoma (mpdac) patients (pts). Annals of oncology : official journal of the European Society for Medical Oncology, 28, iii150. https://doi.org/10.1093/annonc/mdx302.001